Excipients and Formulation Assessments of Complex Generic Products

Paperless manufacturing is a big step for pharma companies. Manufacturers are continuously looking for innovative ways to accelerate new and existing plants and processes.

Despite the efforts towards malaria eradication, the latest estimates show that the number of cases is rising and malaria continues to have a devastating impact on the most vulnerable populations.

Current diagnostic methods for lower respiratory specimens typically take one to two days to identify most bacterial pathogens. During that time, clinicians must rely on guideline recommendations and clinical diagnosis to guide empiric therapy, which is not optimized based on the patient’s individual pathogen. The BioFire Pneumonia Panel will provide pathogen identification in a much shorter timeframe and may allow clinicians to optimize targeted pathogen-specific therapy sooner. The BioFire Pneumonia Panel is a rapid multiplex-PCR test that identifies 33 targets, including 18 bacteria, 8 viruses and 7 antimicrobial resistance genes from lower respiratory tract specimens in about an hour. It provides semi-quantitative results (in copies/ml) for 15 of the bacterial targets. This new feature provided by multiplex-PCR testing may help clinicians and laboratorians separate colonizing from pathogenic levels of bacteria.

Find out which market-moving events and catalysts to watch for during the upcoming Q1 Outlook Webinar - Key catalysts and their impact on pharma markets. During this webinar recording, industry analysts from Informa Pharma Intelligence present their data-based views on what’s in store for key drugs in early 2019. Discussion include important upcoming events related to these key drugs, their likelihood of phase/PDUFA review success and likelihood of approval, and an examination of the market significance of the drugs themselves.